Clinical applications of PET/MRI: Current status and future perspectives

Diagnostic and Interventional Radiology

Volumn 20, Issue 5, 2014, Pages 438-447

  Nensa, Felix ^a   Beiderwellen, Karsten ^a   Heusch, Philipp ^b   Wetter, Axel ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; HUMAN; MULTIMODAL IMAGING; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIMODAL IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84906772142     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.5152/dir.2014.14008     Document Type: Review

References (70)

1. Slomka PJ, Baum RP. Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imaging 2009; 36 (Suppl 1):S44-S55.
2. Zaidi H, Ojha N, Morich M, et al. Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol 2011; 56:3091-3106.
3. Veit-Haibach P, Kuhn FP, Wiesinger F, Del-so G, von Schulthess G. PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine. MAGMA 2013; 26:25-35.
4. Pichler BJ, Swann BK, Rochelle J, Nutt RE, Cherry SR, Siegel SB. Lutetium oxyor-thosilicate block detector readout by avalanche photodiode arrays for high resolution animal PET. Phys Med Biol 2004; 49:4305-4319.
5. Yoon HS, Ko GB, Kwon SI, et al. Initial results of simultaneous PET/MRI experiments with an MRI-compatible silicon photomultiplier PET scanner. J Nucl Med 2012; 53:608-614.
6. Martinez-Möller A, Souvatzoglou M, Del-so G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 2009; 50:520-526.
7. Ma J. Dixon techniques for water and fat imaging. J Magn Reson Imaging 2008; 28:543-558.
8. Kim JH, Lee JS, Song IC, Lee DS. Comparison of segmentation-based attenuation correction methods for PET/MRI: evaluation of bone and liver standardized uptake value with oncologic PET/CT data. J Nucl Med 2012; 53:1878-1882.
9. Delso G, Fürst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 2011; 52:1914-1922.
10. Quick HH. Integrated PET/MR. J Magn Reson Imaging 2013; 39:243-258.
11. Hirsch FW, Sattler B, Sorge I, et al. PET/ MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol 2013; 43:860-875.
12. Jones T, Budinger TF. The potential for low-dose functional studies in maternal-fetal medicine using PET/MR imaging. J Nucl Med 2013; 54:2016-2017.
13. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/ CT in patients with oncologic diagnoses. J Nucl Med 2012; 53:845-855.
14. Quick HH, von Gall C, Zeilinger M, et al. Integrated whole-body PET/MR hybrid imaging: clinical experience. Invest Radi-ol 2013; 48:280-289.
15. Wetter A, Lipponer C, Nensa F, et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest Radiol 2013; 48:256-262.
16. Beiderwellen KJ, Poeppel TD, Har-tung-Knemeyer V, et al. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendo-crine tumors: initial results. Invest Radiol 2013; 48:273-279.
17. Catalano OA, Rosen BR, Sahani DV, et al. Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients-a hypothesis-generating exploratory study. Radiology 2013; 269:857-869.
18. Plathow C, Aschoff P, Lichy MP, et al. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results. Invest Radiol 2008; 43:290-297.
19. Ohno Y, Koyama H, Yoshikawa T, et al. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology 2011; 261:605-615.
20. Schwenzer NF, Schraml C, Müller M, et al. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study. Radiology 2012; 264:551-558.
21. Kohan AA, Kolthammer JA, Verch-er-Conejero JL, et al. N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience. Eur Radiol 2013; 23:3161-3169.
22. Chandarana H, Heacock L, Rakheja R, et al. Pulmonary nodules in patients with primary malignancy: comparison of hybrid PET/MR and PET/CT imaging. Radiology 2013; 268:874-881.
23. Heusch P, Köhler J, Wittsack HJ, et al. Hybrid [(18)F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC). Eur J Radiol 2013; 82:2055-2060.
24. Heusch P, Buchbender C, Köhler J, et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/ MRI in non-small cell lung cancer (NS-CLC) lesions: initial results. Rofo 2013; 185:1056-1062.
25. Mak D, Corry J, Lau E, Rischin D, Hicks RJ. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging 2011; 55:487-499.
26. Boss A, Stegger L, Bisdas S, et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol 2011; 21:1439-1446.
27. Platzek I, Beuthien-Baumann B, Schneider M, et al. PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging 2013; 40:6-11.
28. Varoquaux A, Rager O, Poncet A, et al. Detection and quantification of focal uptake in head and neck tumours: (18)F-FDG PET/ MR versus PET/CT. Eur J Nucl Med Mol Imaging 2013; 41(3):462-475.
29. Kubiessa K, Purz S, Gawlitza M, et al. Initial clinical results of simultaneous (18) F-FDG PET/MRI in comparison to (18) F-FDG PET/CT in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2014; 41:639-648.
30. Schreiter NF, Nogami M, Steffen I, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol 2012; 22:458-467.
31. 18F]-FDG PET/ MRI. Eur J Radiol 2013; 82:e669-e675.
32. Reiner CS, Stolzmann P, Husmann L, et al. Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. Eur J Nucl Med Mol Imaging 2014; 41:649-658.
33. Murphy G, Haider M, Ghai S, Sreeharsha B. The expanding role of MRI in prostate cancer. AJR Am J Roentgenol 2013; 201:1229-1238.
34. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluoro-choline for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012; 15:45-55.
35. Souvatzoglou M, Eiber M, Takei T, et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40:1486-1499.
36. Wetter A, Lipponer C, Nensa F, et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur J Nucl Med Mol Imaging 2014; 41:79-88.
37. Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [68Ga]gallium-la-belled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40:486-495.
38. Eiber M, Takei T, Souvatzoglou M, et al. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med 2013; 55:191-197.
39. Platzek I, Beuthien-Baumann B, Langner J, et al. PET/MR for therapy response evaluation in malignant lymphoma: ini tial experience. MAGMA 2013; 26:49-55.
40. Appenzeller P, Mader C, Huellner MW, et al. PET/CT versus body coil PET/MRI: how low can you go? Insights Imaging 2013; 4:481-490.
41. Schlosser T, Nensa F, Mahabadi AA, Poep-pel TD. Hybrid MRI/PET of the heart: a new complementary imaging technique for simultaneous acquisition of MRI and PET data. Heart 2012; 99:351-352.
42. Ibrahim T, Nekolla SG, Langwieser N, et al. Simultaneous positron emission tomography/magnetic resonance imaging identifies sustained regional abnormalities in cardiac metabolism and function in stress-induced transient midventricular ballooning syndrome. Circulation 2012; 126:e324-e326.
43. Nensa F, Poeppel TD, Beiderwellen K, et al. Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology 2013; 268:366-373.
44. White JA, Rajchl M, Butler J, Thompson RT, Prato FS, Wisenberg G. Active cardiac sarcoidosis: first clinical experience of simultaneous positron emission tomography-magnetic resonance imaging for the diagnosis of cardiac disease. Circulation 2013; 127:e639-e641.
45. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation 2008; 117:103-114.
46. Hunold P, Brandt-Mainz K, Freudenberg L, et al. Evaluation of myocardial viability with contrast-enhanced magnetic resonance imaging--comparison of the late enhancement technique with posi-tronemission tomography. Fortschr Rönt-genstr 2002; 174:867-873.
47. Higuchi T, Nekolla SG, Jankaukas A, et al. Characterization of normal and infarcted rat myocardium using a combination of small-animal PET and clinical MRI. J Nucl Med 2007; 48:288-294.
48. Nensa F, Poeppel TD, Beiderwellen KJ, et al. Cardiac PET/MRI with 18F-FDG: Feasibility and initial results in patients with acute myocardial infarction. Paper presented at: 2013 Annual Meeting of the Radiological Society of North America; December 3, 2013; Chicago, USA.
49. Haroon A, Zumla A, Bomanji J. Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders. Clin Infect Dis 2012; 54:1333-1341.
50. Lurz P, Eitel I, Adam J, et al. Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. JACC Cardiovasc Imaging 2012; 5:513-524.
51. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009; 53:1475-1487.
52. Carbone I, Friedrich MG. Myocardial edema imaging by cardiovascular magnetic resonance: current status and future potential. Curr Cardiol Rep 2012; 14:1-6.
53. Sobic-Saranovic DP, Grozdic IT, Vide-novic-Ivanov J, et al. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis. Clin Nucl Med 2013; 38:516-521.
54. O'Meara C, Menezes LJ, White SK, Wicks E, Elliott P. Inital experience of imaging cardiac sarcoidosis using hybrid PET-MR - a technologist's case study. J Cardiovasc Magn Reson 2013; 15:T1.
55. Schneider S, Batrice A, Rischpler C, Eiber M, Ibrahim T, Nekolla SG. Utility of mul-timodal cardiac imaging with PET/MRI in cardiac sarcoidosis: Implications for diagnosis, monitoring and treatment. Eur Heart J 2014; 35:312.
56. Rahbar K, Seifarth H, Schäfers M, et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med 2012; 53:856-863.
57. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2013; 383:705-713.
58. Ripa RS, Knudsen A, Hag AM, et al. Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging 2013; 3:361-371.
59. Catana C, Benner T, van der Kouwe A, et al. MRI-assisted PET motion correction for neurologic studies in an integrated MR-PET scanner. J Nucl Med 2011; 52:154-161.
60. Price SJ, Gillard JH. Imaging biomark-ers of brain tumour margin and tumour invasion. Br J Radiol 2011; 84 (Spec No 2):S159-S167.
61. Jacobs AH, Thomas A, Kracht LW, et al. 18F-fluoro-L-thymidine and 11C-methyl-methionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005; 46:1948-1958.
62. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/ MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 2010; 51:1198-1205.
63. Schwenzer NF, Stegger L, Bisdas S, et al. Simultaneous PET/MR imaging in a human brain PET/MR system in 50 patients--cur-rent state of image quality. Eur J Radiol 2012; 81:3472-3478.
64. Corroyer-Dulmont A, Pérès EA, Petit E, et al. Detection of glioblastoma response to temozolomide combined with bevaci-zumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol 2013; 15:41-56.
65. Bisdas S, Ritz R, Bender B, et al. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes. Invest Radiol 2013; 48:295-301.
66. Dukart J, Mueller K, Horstmann A, et al. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One 2011; 6:e18111.
67. Moodley KK, Minati L, Barnes A, Dickson JC, Ell PJ, Chan D. Simultaneous PET/MRI in frontotemporal dementia. Eur J Nucl Med Mol Imaging 2013; 40:468-469.
68. Becker GA, Ichise M, Barthel H, et al. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med 2013; 54:723-731.
69. Salamon N, Kung J, Shaw SJ, et al. FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy. Neurology 2008; 71:1594-1601.
70. Mueller WP, Melzer HI, Schmid I, Coppenrath E, Bartenstein P, Pfluger T. The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. Eur J Nucl Med Mol Imaging 2013; 40:356-363.